[go: up one dir, main page]

BR9609989A - Compostos de benzilaminopiperidina substituídos - Google Patents

Compostos de benzilaminopiperidina substituídos

Info

Publication number
BR9609989A
BR9609989A BR9609989A BR9609989A BR9609989A BR 9609989 A BR9609989 A BR 9609989A BR 9609989 A BR9609989 A BR 9609989A BR 9609989 A BR9609989 A BR 9609989A BR 9609989 A BR9609989 A BR 9609989A
Authority
BR
Brazil
Prior art keywords
compounds
substituted
substituted benzylaminopiperidine
benzylaminopiperidine compounds
benzylaminopiperidine
Prior art date
Application number
BR9609989A
Other languages
English (en)
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9609989A publication Critical patent/BR9609989A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9609989A 1995-08-24 1996-06-10 Compostos de benzilaminopiperidina substituídos BR9609989A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24
PCT/IB1996/000572 WO1997008144A1 (en) 1995-08-24 1996-06-10 Substituted benzylaminopiperidine compounds

Publications (1)

Publication Number Publication Date
BR9609989A true BR9609989A (pt) 1999-07-06

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609989A BR9609989A (pt) 1995-08-24 1996-06-10 Compostos de benzilaminopiperidina substituídos

Country Status (41)

Country Link
US (1) US6506775B1 (pt)
EP (2) EP0861235B1 (pt)
JP (1) JP3084069B2 (pt)
KR (1) KR100288673B1 (pt)
CN (1) CN1153764C (pt)
AP (1) AP643A (pt)
AR (1) AR006305A1 (pt)
AT (2) ATE258166T1 (pt)
AU (1) AU702698B2 (pt)
BG (1) BG64126B1 (pt)
BR (1) BR9609989A (pt)
CA (1) CA2227814C (pt)
CO (1) CO4480738A1 (pt)
CZ (1) CZ297543B6 (pt)
DE (2) DE69631390T2 (pt)
DK (2) DK1114817T3 (pt)
DZ (1) DZ2086A1 (pt)
ES (2) ES2163017T3 (pt)
HR (1) HRP960386B1 (pt)
HU (1) HU225480B1 (pt)
IL (1) IL119078A (pt)
IS (1) IS1947B (pt)
MA (1) MA23961A1 (pt)
MX (1) MX9801467A (pt)
MY (1) MY114800A (pt)
NO (1) NO310720B1 (pt)
NZ (1) NZ308207A (pt)
OA (1) OA10666A (pt)
PE (2) PE1398A1 (pt)
PL (1) PL186773B1 (pt)
PT (2) PT861235E (pt)
RO (1) RO119299B1 (pt)
RU (1) RU2152930C2 (pt)
SI (2) SI0861235T1 (pt)
SK (1) SK282925B6 (pt)
TN (1) TNSN96107A1 (pt)
TR (1) TR199800300T1 (pt)
TW (1) TW340842B (pt)
UA (1) UA48981C2 (pt)
WO (1) WO1997008144A1 (pt)
YU (1) YU49122B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
IL145945A0 (en) * 1999-05-06 2002-07-25 Pfizer Prod Inc Substituted benzolactam compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
CA2374643C (en) * 1999-05-21 2006-02-14 Pfizer Products Inc. 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
DK1095939T3 (da) * 1999-10-18 2004-04-13 Pfizer Prod Inc Fremgangsmåde til fremstilling af cykliske piperidinylaminomethyltrifluormethyletherforbindelser
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100885986B1 (ko) 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
ES2388547T3 (es) 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
CA2566920A1 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2247185B1 (en) 2008-03-03 2014-04-16 Tiger Pharmatech Tyrosine kinase inhibitors
EP2264029A4 (en) 2008-03-31 2011-08-24 Kowa Co 1,3-dihydroisobenzofuran DERIVATIVE
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
JP5764553B2 (ja) 2009-05-12 2015-08-19 アルバニー モレキュラー リサーチ, インコーポレイテッド 7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンおよびその使用
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN103282497B (zh) 2010-08-17 2018-07-10 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 癌を処置するための組成物および方法
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
KR20210046009A (ko) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 Prmt5 억제제
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
RU2105001C1 (ru) * 1991-03-26 1998-02-20 Пфайзер Инк. Способ получения замещенных 3-аминопиперидинов
RU2114848C1 (ru) * 1991-06-20 1998-07-10 Пфайзер Инк. Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ ингибирования действия вещества р у млекопитающих
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
JP3992733B2 (ja) 1995-03-27 2007-10-17 久光製薬株式会社 ピペリジン誘導体
ATE223896T1 (de) * 1995-12-21 2002-09-15 Pfizer 3-((5-substituierte benzyl)amino)-2- phenylpiperidine als substance-p-antagonisten
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
SK282925B6 (sk) 2003-01-09
CZ52198A3 (cs) 1999-01-13
KR19990044077A (ko) 1999-06-25
JP3084069B2 (ja) 2000-09-04
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
RU2152930C2 (ru) 2000-07-20
KR100288673B1 (ko) 2001-05-02
DE69616817D1 (de) 2001-12-13
IL119078A (en) 2003-11-23
SK20798A3 (en) 1999-03-12
PL325332A1 (en) 1998-07-20
DE69616817T2 (de) 2002-04-04
BG64126B1 (bg) 2004-01-30
MX9801467A (es) 1998-05-31
OA10666A (en) 2002-11-25
EP1114817B1 (en) 2004-01-21
DK0861235T3 (da) 2001-12-27
AP9600850A0 (en) 1996-10-31
IS4644A (is) 1997-12-30
HRP960386A2 (en) 1998-04-30
NO980751L (no) 1998-02-23
ES2211684T3 (es) 2004-07-16
HRP960386B1 (en) 2002-04-30
AU702698B2 (en) 1999-03-04
CA2227814A1 (en) 1997-03-06
SI0861235T1 (en) 2002-04-30
WO1997008144A1 (en) 1997-03-06
TW340842B (en) 1998-09-21
NZ308207A (en) 1998-07-28
YU47896A (sh) 1998-12-23
ATE258166T1 (de) 2004-02-15
CN1153764C (zh) 2004-06-16
TR199800300T1 (xx) 1998-06-22
ATE208377T1 (de) 2001-11-15
CO4480738A1 (es) 1997-07-09
PE20010700A1 (es) 2001-07-09
DZ2086A1 (fr) 2002-07-22
HUP9901159A2 (hu) 1999-07-28
NO310720B1 (no) 2001-08-20
TNSN96107A1 (fr) 2005-03-15
HUP9901159A3 (en) 2000-05-29
CN1193961A (zh) 1998-09-23
DK1114817T3 (da) 2004-04-26
PT861235E (pt) 2002-03-28
IL119078A0 (en) 1996-11-14
JPH10510554A (ja) 1998-10-13
EP0861235B1 (en) 2001-11-07
RO119299B1 (ro) 2004-07-30
SI1114817T1 (en) 2004-06-30
IS1947B (is) 2004-10-13
HK1014935A1 (en) 1999-10-08
AR006305A1 (es) 1999-08-25
CZ297543B6 (cs) 2007-02-07
EP1114817A1 (en) 2001-07-11
PE1398A1 (es) 1998-02-27
ES2163017T3 (es) 2002-01-16
PL186773B1 (pl) 2004-02-27
EP0861235A1 (en) 1998-09-02
MA23961A1 (fr) 1997-04-01
UA48981C2 (uk) 2002-09-16
US6506775B1 (en) 2003-01-14
MY114800A (en) 2003-01-31
CA2227814C (en) 2002-12-31
AP643A (en) 1998-04-24
NO980751D0 (no) 1998-02-23
PT1114817E (pt) 2004-05-31
AU5776996A (en) 1997-03-19
BG102288A (en) 1998-09-30
DE69631390T2 (de) 2004-11-25
YU49122B (sh) 2004-03-12

Similar Documents

Publication Publication Date Title
BR9609989A (pt) Compostos de benzilaminopiperidina substituídos
ID16345A (id) Senyawa-senyawa heterosiklik
BR9607097A (pt) Novos compostos
BR9600534A (pt) Novos compostos
DE59609887D1 (de) Substituierte cyanophenyluracile
BR9609682A (pt) Foto-desinfetantes de baixa nuança
DE69608259D1 (de) Verbunddamenbinde
BR9600251A (pt) Composto
IS4739A (is) Efnasambönd
NO974170D0 (no) Polyazacykloalkan-forbindelser
DE59610332D1 (de) Substituierte aminouracile
PT923594E (pt) Compostos de bromotiacumicina
BR9609319A (pt) Carbonilaminofeniluracilas substituídas
BR9601295A (pt) Composto
BR9608890A (pt) N-metilenotiouréias substituídas
BR9611576A (pt) Composto
ATE198470T1 (de) Alkenyl-benzoylguanidine
BR9603376A (pt) Tetrahidro-5-nitro-pirimidinas substituídas
PT839024E (pt) Formulacoes de monensina
DE59607732D1 (de) Substituierte benzylidencyanessigester
ATE240972T1 (de) Cyclopeptolide
DE59607958D1 (de) Substituierte phenyluracile
ID18956A (id) Senyawa-senyawa herbisida
EP0757075A3 (en) Polyaminotriazine composition
BR9610194A (pt) Aminouracilas substituídas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NOS ARTIGOS 8, 11, 13 E 24 DA LPI NO 9.279/1.996.